Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Postmenopausal Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017

172 views

Published on

Postmenopausal Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017SummaryGlobalData, the industry analysis specialist, has released its new report, 'Postmenopausal Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017'. The report is an essential source of information and analysis on the global Post Menopausal Osteoporosis Therapeutics market. The report identifies the key trends shaping and driving the global Post Menopausal Osteoporosis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Post Menopausal Osteoporosis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.ScopeThe report provides information on the key drivers and challenges of the Post Menopausal Osteoporosis Therapeutics market. Its scope includes - - Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Post Menopausal Osteoporosis Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017. - Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.- Analysis of the current and future competition in the seven key countries Post Menopausal Osteoporosis Therapeutics market. - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. - Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Post Menopausal Osteoporosis Therapeutics therapeutics market.- Analysis of key recent licensing and partnership agreements in Post Menopausal Osteoporosis Therapeutics marketReasons to buyThe report will enhance your decision making capability. It will allow you to - - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global Post Menopausal Osteoporosis Therapeutics market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Post Menopausal Osteoporosis Therapeutics market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. - What's the next big thing in the global Post Menopausal Osteoporosis Therapeutics market landscape' ' Identify, understand and capitalize.

  • Be the first to comment

  • Be the first to like this

Postmenopausal Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017

  1. 1. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Postmenopausal Osteoporosis Therapeutics - Pipeline Assessmentand Market Forecasts to 2017Published on August 2011 Report SummaryPostmenopausal Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017SummaryGlobalData, the industry analysis specialist, has released its new report, Postmenopausal Osteoporosis Therapeutics - PipelineAssessment and Market Forecasts to 2017. The report is an essential source of information and analysis on the global PostMenopausal Osteoporosis Therapeutics market. The report identifies the key trends shaping and driving the global Post MenopausalOsteoporosis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emergingplayers expected to significantly alter the market positioning of the current market leaders. Most importantly, the report providesvaluable insights on the pipeline products within the global Post Menopausal Osteoporosis Therapeutics sector. This report is builtusing data and information sourced from proprietary databases, primary and secondary research and in-house analysis byGlobalDatas team of industry experts.ScopeThe report provides information on the key drivers and challenges of the Post Menopausal Osteoporosis Therapeutics market. Itsscope includes -- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Post Menopausal Osteoporosis Therapeuticsmarket revenues data from 2005 to 2009, forecast for eight years to 2017.- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends byseven key markets. Pipeline candidates fall under major therapeutic classes.- Analysis of the current and future competition in the seven key countries Post Menopausal Osteoporosis Therapeutics market.- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide aqualitative analysis of its implications.- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the PostMenopausal Osteoporosis Therapeutics therapeutics market.- Analysis of key recent licensing and partnership agreements in Post Menopausal Osteoporosis Therapeutics marketReasons to buyThe report will enhance your decision making capability. It will allow you to -- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and byidentifying the companies with the most robust pipeline.- Develop business strategies by understanding the trends shaping and driving the global Post Menopausal OsteoporosisTherapeutics market.- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely toimpact the global Post Menopausal Osteoporosis Therapeutics market in future.- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance ofvarious competitors.Postmenopausal Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017 (From Slideshare) Page 1/8
  2. 2. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitiveadvantage.- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunitiesfor consolidations, investments and strategic partnerships.- Whats the next big thing in the global Post Menopausal Osteoporosis Therapeutics market landscape Identify, understand andcapitalize. Table of Content1 Table of Contents1 Table of Contents 31.1 List of Tables 51.2 List of Figures 62 Postmenopausal Osteoporosis Therapeutics: Introduction 72.1 Disease Overview 72.2 Epidemiology 92.3 Etiology 102.4 Pathophysiology 102.5 Signs and Symptoms 112.6 Diagnosis 112.6.1 Medical History 112.6.2 BMD Testing 122.6.3 Laboratory Tests 132.7 Treatment and Management Options 142.8 GlobalData Pipeline Report Guidance 163 Postmenopausal Osteoporosis Therapeutics: Market Characterization 173.1 Postmenopausal Osteoporosis Therapeutics Market Size (2005-2010) Global 173.2 Postmenopausal Osteoporosis Therapeutics Market Forecast (2010-2017) Global 183.3 Postmenopausal Osteoporosis Therapeutics Market Size (2005-2010) The US 203.4 Postmenopausal Osteoporosis Therapeutics Market Forecast (2010-2017) The US 213.5 Postmenopausal Osteoporosis Therapeutics Market Size (2005-2010) France 223.6 Postmenopausal Osteoporosis Therapeutics Market Forecast (2010-2017) France 233.7 Postmenopausal Osteoporosis Therapeutics Market Size (2005-2010) Germany 243.8 Postmenopausal Osteoporosis Therapeutics Market Forecast (2010-2017) Germany 253.9 Postmenopausal Osteoporosis Therapeutics Market Size (2005-2010) Italy 263.10 Postmenopausal Osteoporosis Therapeutics Market Forecast (2010-2017) Italy 273.11 Postmenopausal Osteoporosis Therapeutics Market Size (2005-2010) Spain 283.12 Postmenopausal Osteoporosis Therapeutics Market Forecast (2010-2017) Spain 293.13 Postmenopausal Osteoporosis Therapeutics Market Size (2005-2010) The UK 303.14 Postmenopausal Osteoporosis Therapeutics Market Forecast (2010-2017) The UK 313.15 Postmenopausal Osteoporosis Therapeutics Market Size (2005-2010) Japan 323.16 Postmenopausal Osteoporosis Therapeutics Market Forecast (2010-2017) Japan 333.17 Drivers and Barriers for the Postmenopausal Osteoporosis Therapeutics Market 343.17.1 Drivers for the Postmenopausal Osteoporosis Therapeutics Market 343.17.2 Barriers for the Postmenopausal Osteoporosis Therapeutics Market 353.18 Opportunity and Unmet Need Analysis 36Postmenopausal Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017 (From Slideshare) Page 2/8
  3. 3. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!3.19 Key Takeaway 374 Postmenopausal Osteoporosis Therapeutics: Competitive Assessment 384.1 Overview 384.2 Strategic Competitor Assessment 384.3 Product Profiles for the Major Marketed Products in the Postmenopausal Osteoporosis Therapeutics Market 394.3.1 Fosamax (alendronate sodium) 394.3.2 Actonel (risedronate sodium) 414.3.3 Boniva (ibandronate sodium) 434.3.4 Reclast (zoledronic acid) 444.3.5 Evista (raloxifene hydrochloride) 454.3.6 Prolia (denosumab) 474.3.7 Forteo (teriparatide [rDNA origin]) injection 484.3.8 Miacalcin (salmon calcitonin) 504.3.9 Activella (estradiol, norethindrone acetate) 504.3.10 Premarin (estrogen) 524.3.11 Prempro (conjugated estrogens and medroxyprogesterone acetate) 524.4 Key Takeaway 535 Postmenopausal Osteoporosis Therapeutics: Pipeline Assessment 545.1 Overview 545.2 Strategic Pipeline Assessment 545.3 Postmenopausal Osteoporosis Therapeutics Pipeline by Phases of Development 545.3.1 Postmenopausal Osteoporosis Therapeutics Phase III Pipeline 555.3.2 Postmenopausal Osteoporosis Therapeutics Phase II Pipeline 555.3.3 Postmenopausal Osteoporosis Therapeutics Phase I Pipeline 555.3.4 Postmenopausal Osteoporosis Market Pre-Clinical Pipeline 555.3.5 Technology Trends Analytic Framework 565.4 Postmenopausal Osteoporosis Therapeutics Market Clinical Pipeline by Mechanism of Action 585.5 Postmenopausal Osteoporosis Therapeutics Promising Drugs Under Clinical Development 595.6 Molecule Profile for Promising Drugs Under Clinical Development 595.6.1 Odanacatib (MK-0822) 595.6.2 PREOS (parathyroid hormone 1-84 [rDNA origin] injection) 605.6.3 NB S101 605.6.4 SMC021 615.7 Key Takeaway 616 Postmenopausal Osteoporosis Therapeutics: Clinical Trials Mapping 626.1 Clinical Trials by Region/Country (The US, EU5 and Japan) 626.2 Clinical Trials by Phase 636.3 Clinical Trials by Trial Status 646.4 Prominent Sponsors 656.5 Clinical Trials by Overall Sponsors 666.6 Top Companies Participating in Postmenopausal Osteoporosis Therapeutics Clinical Trials 677 Postmenopausal Osteoporosis Therapeutics: Strategic Assessment 687.1 Key Events Impacting the Future Market 687.2 Postmenopausal Osteoporosis Therapeutics: Implications for Future Market Competition 688 Postmenopausal Osteoporosis Therapeutics: Future Players 708.1 Introduction 708.2 Company Profiles 718.2.1 Amgen Inc. 71Postmenopausal Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017 (From Slideshare) Page 3/8
  4. 4. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!8.2.2 Merck & Co., Inc. 738.2.3 Novartis AG 768.2.4 NPS Pharmaceuticals 808.2.5 Osteologix, Inc. 828.2.6 Other Companies in the Postmenopausal Osteoporosis Market 849 Postmenopausal Osteoporosis Therapeutics: Licensing & Partnership Deals 8510 Postmenopausal Osteoporosis Therapeutics: Appendix 8710.1 Market Definitions 8710.2 Abbreviations 8710.3 Methodology 8810.3.1 Coverage 8810.3.2 Secondary Research 8910.3.3 Forecasting 8910.3.4 Primary Research 9210.3.5 Expert Panel Validation 9210.4 Contact Us 9210.5 Disclaimer 9210.6 Bibliography 931.1 List of TablesTable 1: Difference Between Type I and Type II Osteoporosis 8Table 2: Osteoporosis Prevalence and Low Bone Mass in People Aged 50 and Over (The US) (million)* 9Table 3: Difference Between Diagnostic Techniques Used for BMD Measurement 12Table 4: WHO Classification for Diagnosis of Osteoporosis Using BMD Measurements 13Table 5: Approved Drugs for the Prevention and Treatment of Postmenopausal Osteoporosis 15Table 6: Postmenopausal Osteoporosis Therapeutics Market, Global, Revenue ($bn), 20052010 18Table 7: Postmenopausal Osteoporosis Therapeutics Market, Global, Forecast ($bn), 20102017 19Table 8: Postmenopausal Osteoporosis Therapeutics Market, The US, Revenue ($bn), 20052010 20Table 9: Postmenopausal Osteoporosis Therapeutics Market, The US, Forecast ($bn), 20102017 21Table 10: Postmenopausal Osteoporosis Therapeutics Market, France, Revenue ($m), 20052010 22Table 11: Postmenopausal Osteoporosis Therapeutics Market, France, Forecast ($m), 20102017 23Table 12: Postmenopausal Osteoporosis Therapeutics Market, Germany, Revenue ($m), 20052010 24Table 13: Postmenopausal Osteoporosis Therapeutics Market, Germany, Forecast ($m), 20102017 25Table 14: Postmenopausal Osteoporosis Therapeutics Market, Italy, Revenue ($m), 20052010 26Table 15: Postmenopausal Osteoporosis Therapeutics Market, Italy, Forecast ($m), 20102017 27Table 16: Postmenopausal Osteoporosis Therapeutics Market, Spain, Revenue ($m), 20052010 28Table 17: Postmenopausal Osteoporosis Therapeutics Market, Spain, Forecast ($m), 20102017 29Table 18: Postmenopausal Osteoporosis Therapeutics Market, The UK, Revenue ($m), 20052010 30Table 19: Postmenopausal Osteoporosis Therapeutics Market, The UK, Forecast ($m), 20102017 31Table 20: Postmenopausal Osteoporosis Therapeutics Market, Japan, Revenue ($m), 20052010 32Table 21: Postmenopausal Osteoporosis Therapeutics Market, Japan, Forecast ($m), 20102017 33Table 22: Effect of Actonel on the Risk of Vertebral Fractures 42Table 23: Effect of Evista on Risk of Vertebral Fractures 46Table 24: Effect of Evista on Increases in BMD vs. Placebo 47Table 25: Effect of Forteo on Risk of Vertebral Fractures in Postmenopausal Women with Osteoporosis 49Table 26: Mean Percentage Change in BMD in Postmenopausal Women with Osteoporosis 49Table 27: Postmenopausal Osteoporosis Therapeutics Phase III Pipeline, 2010 55Postmenopausal Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017 (From Slideshare) Page 4/8
  5. 5. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Table 28: Postmenopausal Osteoporosis Therapeutics Phase II Pipeline, 2010 55Table 29: Postmenopausal Osteoporosis Therapeutics Phase I Pipeline, 2010 55Table 30: Postmenopausal Osteoporosis Therapeutics Pre-Clinical Pipeline, 2010 55Table 31: Postmenopausal Osteoporosis Therapeutics Most Promising Drugs Under Clinical Development, 2010 59Table 32: Postmenopausal Osteoporosis Therapeutics Market Clinical Trials by Region/ Country, 2010 62Table 33: Postmenopausal Osteoporosis Therapeutics Clinical Trials by Phase, 2010 63Table 34: Postmenopausal Osteoporosis Therapeutics Clinical Trials by Status, 2010 64Table 35: Postmenopausal Osteoporosis Therapeutics Prominent Sponsors, 2010 65Table 36: Postmenopausal Osteoporosis Therapeutics Overall Sponsors, 2010 66Table 37: Postmenopausal Osteoporosis Therapeutics Top Companies Participating in Therapeutics Clinical Trials, 2010 67Table 38: Amgen Inc. Deals, Alliances and Partnership 72Table 39: Merck & Co., Inc. Deals, Alliances and Partnership 74Table 40: Merck & Co., Inc. Womens Health Pipeline, 2010 76Table 41: Novartis AG Deals, Alliances and Partnership 78Table 42: Novartis AG - Womens Health Pipeline Products, 2010 79Table 43: NPS Pharmaceuticals Deals, Alliances and Partnership 81Table 44: NPS Pharmaceuticals Womens Health Pipeline, 2010 81Table 45: Osteologix, Inc. Deals, Alliances and Partnership 83Table 46: Osteologix, Inc. Womens Health Pipeline, 2010 83Table 47: Postmenopausal Osteoporosis Therapeutics Market Future Players 84Table 48: Postmenopausal Osteoporosis Therapeutics, Global, Deals 851.2 List of FiguresFigure 1: Variation in the Levels of Bone Density with Age in Females 7Figure 2: Classification of Osteoporosis 8Figure 3: Postmenopausal Osteoporosis Therapeutics Market, Global, Revenue ($bn), 20052010 17Figure 4: Postmenopausal Osteoporosis Therapeutics Market, Global, Forecast ($bn), 20102017 19Figure 5: Postmenopausal Osteoporosis Therapeutics Market, The US, Revenue ($bn), 20052010 20Figure 6: Postmenopausal Osteoporosis Therapeutics Market, The US, Forecast ($bn), 20102017 21Figure 7: Postmenopausal Osteoporosis Therapeutics Market, France, Revenue ($m), 20052010 22Figure 8: Postmenopausal Osteoporosis Therapeutics Market, France, Forecast ($m), 20102017 23Figure 9: Postmenopausal Osteoporosis Therapeutics Market, Germany, Revenue ($m), 20052010 24Figure 10: Postmenopausal Osteoporosis Therapeutics Market, Germany, Forecast ($m), 20102017 25Figure 11: Postmenopausal Osteoporosis Therapeutics Market, Italy, Revenue ($m), 20052010 26Figure 12: Postmenopausal Osteoporosis Therapeutics Market, Italy, Forecast ($m), 20102017 27Figure 13: Postmenopausal Osteoporosis Therapeutics Market, Spain, Revenue ($m), 20052010 28Figure 14: Postmenopausal Osteoporosis Therapeutics Market, Spain, Forecast ($m), 20102017 29Figure 15: Postmenopausal Osteoporosis Therapeutics Market, The UK, Revenue ($m), 20052010 30Figure 16: Postmenopausal Osteoporosis Therapeutics Market, The UK, Forecast ($m), 20102017 31Figure 17: Postmenopausal Osteoporosis Therapeutics Market, Japan, Revenue ($m), 20052010 32Figure 18: Postmenopausal Osteoporosis Therapeutics Market, Japan, Forecast ($m), 20102017 33Figure 19: Opportunity and Unmet Need in the Postmenopausal Osteoporosis Therapeutics Market 36Figure 20: Postmenopausal Osteoporosis Therapeutics Strategic Competitor Assessment, 2010 39Figure 21: Postmenopausal Osteoporosis Therapeutics Pipeline by Phase of Development, 2010 54Figure 22: Postmenopausal Osteoporosis Therapeutics Technology Trends Analytics Framework, 2010 56Figure 23: Postmenopausal Osteoporosis Therapeutics Technology Trends Analytics Framework Description, 2010 57Figure 24: Postmenopausal Osteoporosis Therapeutics Pipeline by Mechanism of Action, 2010 58Postmenopausal Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017 (From Slideshare) Page 5/8
  6. 6. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Figure 25: Postmenopausal Osteoporosis Therapeutics Clinical Trials by Country, 2010 62Figure 26: Postmenopausal Osteoporosis Therapeutics Clinical Trials by Phase, 2010 63Figure 27: Postmenopausal Osteoporosis Therapeutics Clinical Trials by Status, 2010 64Figure 28: Postmenopausal Osteoporosis Therapeutics Prominent Sponsors, 2010 65Figure 29: Postmenopausal Osteoporosis Therapeutics Overall Sponsors, 2010 66Figure 30: Postmenopausal Osteoporosis Therapeutics Top Companies Participating in Therapeutics Clinical Trials, 2010 67Figure 31: Postmenopausal Osteoporosis Therapeutics Market Drivers and Restraints 2010 68Figure 32: Implications for Future Market Competition in the Postmenopausal Osteoporosis Market, 2010 68Figure 33: Postmenopausal Osteoporosis Therapeutics Market Pipeline by Company, 2010 70Figure 34: GlobalData Market Forecasting Model 91Companies mentionedAmgen Inc.Merck & Co., Inc.Novartis AGNPS PharmaceuticalsOsteologix, Inc.Postmenopausal Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017 (From Slideshare) Page 6/8
  7. 7. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require. Postmenopausal Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017 Product Formats Please select the product formats and the quantity you require. 1 User License--USD 2 000.00 Quantity: _____ Site License--USD 4 000.00 Quantity: _____ Corporate License--USD 6 000.00 Quantity: _____ Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________Postmenopausal Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017 (From Slideshare) Page 7/8
  8. 8. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box. Payment by credit card Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________ Payment by wire transfer Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189 Payment by check UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE Customer signature:   Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93Postmenopausal Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017 (From Slideshare) Page 8/8

×